Castration-resistant prostate cancer: latest evidence and therapeutic implications von Suzman, Daniel L., Antonarakis, Emmanuel S.

Volltext

Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents von Suzman, Daniel L., Pelosof, Lorraine, Rosenberg, Amy, Avigan, Mark I.

Volltext

FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non‐Small Cell Lung Cancer With Progression On or After Platinum‐Based Chemotherapy von Kazandjian, Dickran, Suzman, Daniel L., Blumenthal, Gideon, Mushti, Sirisha, He, Kun, Libeg, Meredith, Keegan, Patricia, Pazdur, Richard

Volltext

FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer von Fallah, Jaleh, Agrawal, Sundeep, Gittleman, Haley, Fiero, Mallorie H, Subramaniam, Sriram, John, Christy, Chen, Wei, Ricks, Tiffany K, Niu, Gang, Fotenos, Anthony, Wang, Min, Chiang, Kelly, Pierce, William F, Suzman, Daniel L, Tang, Shenghui, Pazdur, Richard, Amiri-Kordestani, Laleh, Ibrahim, Amna, Kluetz, Paul G

Volltext

Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1–defined disease... von Kazandjian, Dickran, Keegan, Patricia, Suzman, Daniel L, Pazdur, Richard, Blumenthal, Gideon M

Volltext

FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy von Suzman, Daniel L., Agrawal, Sundeep, Ning, Yang‐min, Maher, V. Ellen, Fernandes, Laura L., Karuri, Stella, Tang, Shenghui, Sridhara, Rajeshwari, Schroeder, Jason, Goldberg, Kirsten B., Ibrahim, Amna, McKee, Amy E., Pazdur, Richard, Beaver, Julia A.

Volltext

Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone von Suzman, Daniel L., Luber, Brandon, Schweizer, Michael T., Nadal, Rosa, Antonarakis, Emmanuel S.

Volltext

FDA Approval Summary: Belzutifan for VHL Disease Tumors-Response von Fallah, Jaleh, Weinstock, Chana, Mehta, Gautam U, Brave, Michael H, Pierce, William F, Pazdur, Richard, Nair, Abhilasha, Suzman, Daniel L, Amiri-Kordestani, Laleh

Volltext

An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate Cancer von Brave, Michael, Weinstock, Chana, Brewer, Jamie R., Chi, Dow-Chung, Suzman, Daniel L., Cheng, Joyce, Zhang, Lijun, Sridhara, Rajeshwari, Ibrahim, Amna, Kluetz, Paul G., Pazdur, Richard, Beaver, Julia A.

Volltext

Clinical Implications of Hedgehog Pathway Signaling in Prostate Cancer von Suzman, Daniel L, Antonarakis, Emmanuel S

Volltext

U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review von Arora, Shaily, Narayan, Preeti, Ison, Gwynn, Berman, Tara, Suzman, Daniel L, Wedam, Suparna, Prowell, Tatiana M, Ghosh, Soma, Philip, Reena, Osgood, Christy L, Gao, Jennifer J, Shah, Mirat, Krol, Danielle, Wahby, Sakar, Royce, Melanie, Brus, Christina, Bloomquist, Erik W, Fiero, Mallorie H, Tang, Shenghui, Pazdur, Richard, Ibrahim, Amna, Amiri-Kordestani, Laleh, Beaver, Julia A

Volltext

Bone-targeting agents in prostate cancer von Suzman, Daniel L., Boikos, Sosipatros A., Carducci, Michael A.

Volltext

Regulatory Considerations for Contribution of Effect of Drugs Used in Combination Regimens: Renal Cell Cancer Case Studies von Brewer, Jamie R., Chang, Elaine, Agrawal, Sundeep, Singh, Harpreet, Suzman, Daniel L., Xu, James, Weinstock, Chana, Fernandes, Laura L., Cheng, Joyce, Zhang, Lijun, Xie, Diqiong, Goldberg, Kirsten B., Bloomquist, Erik W., Tang, Shenghui, Sridhara, Rajeshwari, Theoret, Marc R., Pazdur, Richard, Ibrahim, Amna, Beaver, Julia A.

Volltext

Does degree of androgen suppression matter in hormone-sensitive prostate cancer? von Suzman, Daniel L, Antonarakis, Emmanuel S

Volltext

Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis... von Fallah, Jaleh, Zhang, Lijun, Amatya, Anup, Gong, Yutao, King-Kallimanis, Bellinda, Bhatnagar, Vishal, Weinstock, Chana, Suzman, Daniel L, Agrawal, Sundeep, Chang, Elaine, Anscher, Mitchell S, Chi, Dow-Chung, Xu, James X, Brewer, Jamie R, Brave, Michael H, Hadadi, Mehrnoosh, Theoret, Marc R, Kluetz, Paul G, Goldberg, Kirsten B, Ibrahim, Amna, Tang, Shenghui, Pazdur, Richard, Beaver, Julia A, Amiri-Kordestani, Laleh, Singh, Harpreet

Volltext

Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer von Maughan, Benjamin L., Suzman, Daniel L., Luber, Brandon, Wang, Hao, Glavaris, Stephanie, Hughes, Robert, Sullivan, Rana, Harb, Rana, Boudadi, Karim, Paller, Channing, Eisenberger, Mario, Demarzo, Angelo, Ross, Ashely, Antonarakis, Emmanuel S.

Volltext

Exploration of baseline patient-reported side effect bother from cancer therapy von Roydhouse, Jessica K, King-Kallimanis, Bellinda L, Roy, Pourab, Weinstock, Chana, Krol, Danielle, Daniels, Selena R, Suzman, Daniel L, Beaver, Julia A, Kluetz, Paul G

Volltext

Determining the Optimal Treatment for Metastatic Castration-resistant Prostate Cancer: Age Should Not Be a Factor von Suzman, Daniel L, Eisenberger, Mario A

Volltext

Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer von Maughan, Benjamin L., Xhou, Xian C., Suzman, Daniel L., Nadal, Rosa, Bassi, Sunakshi, Schweizer, Michael T., Antonarakis, Emmanuel S.

Volltext

Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer von Boudadi, Karim, Suzman, Daniel L., Anagnostou, Valsamo, Fu, Wei, Luber, Brandon, Wang, Hao, Niknafs, Noushin, White, James R., Silberstein, John L., Sullivan, Rana, Dowling, Donna, Harb, Rana, Nirschl, Thomas R., Veeneman, Brendan A., Tomlins, Scott A., Wang, Yipeng, Jendrisak, Adam, Graf, Ryon P., Dittamore, Ryan, Carducci, Michael A., Eisenberger, Mario A., Haffner, Michael C., Meeker, Alan K., Eshleman, James R., Luo, Jun, Velculescu, Victor E., Drake, Charles G., Antonarakis, Emmanuel S.

Volltext